## **INSTITUTE OF BIOMEDICAL SCIENCE**
**Company Number 377268 Charity Number 261926**
**FINANCIAL STATEMENTS FOR THE**
**YEAR ENDED 31 DECEMBER 2023**
## **INSTITUTE OF BIOMEDICAL SCIENCE CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023**
||**Page**|
|---|---|
|**Council Members’ Report**|1-10|
|**Report of the Independent Auditors**|11-13|
|**Consolidated Statement of Financial**||
|**Activities**|14|
|**Consolidated Balance Sheet**|15|
|**Charity Only Balance Sheet**|16|
|**Consolidated Statement of Cash Flows**|17|
|**Notes to the Financial Statements**|18-32|
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Council Members’ Report**
The Council members, who are also the trustees, submit their report on the charitable company and its group together with the audited financial statements for the year ended 31 December 2023.
## **Reference and Administrative Details**
## _**LEGAL STATUS**_
The Institute is a registered charity, number 261926. It is also registered at Companies House, as a company limited by guarantee and having no share capital, number 377268. The liability of its members, in the event of the company winding up, is limited to £1.
## _**COUNCIL MEMBERS**_
The members of Council, who were the company’s directors and trustees of the charity during the year or on the date of approval of this report, were:
Joanna Andrew Glenn McDowell Victoria Bradley James G McNair (resigned 31 December 2023) Nigel Coles Colin Mudd Jennifer Collins Jane Needham (resigned 3 June 2023) Alan Deacon (appointed 20 October 2023) Debra Padgett David Eccleston Sarah Pitt Charles Houston Sheri Scott Tahmina Hussain Matthew Smith Angela Jean-Francois Andrew Usher Zonya Jeffrey Linda Walsh Azuma Kalu (appointed 3 June 2023)
Each Council member is also a member of the Institute.
## _**CHIEF EXECUTIVE AND COMPANY SECRETARY**_
Mr David Wells
## _**REGISTERED OFFICE**_
12 Coldbath Square, London EC1R 5HL
## _**RELEVANT ORGANISATIONS**_
## **Auditors:**
Haysmacintyre LLP 10 Queen Street Place London EC4R 1AG
## **Bankers:**
National Westminster Bank plc Regent Street Branch 250 Regent Street London W1B 3BN
## **Investment Advisors:**
EPOCH Consulting Queen Square House Queen Square Place Bath BA1 2LL
## **Solicitors:**
Moore Barlow LLP The Oriel Sydenham Road Guilford GU1 3SR
Page 1
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Council Members’ Report (continued)**
## **Structure, Governance and Management**
## _**GOVERNANCE AND INTERNAL CONTROL**_
The Institute is a company limited by guarantee and a registered charity. Its governing document is the Memorandum and Articles of Association, originally incorporated on 17 November 1942, updated 11 June 2022.
## _**COUNCIL MEMBERS**_
Council shall be composed of not fewer than twelve and not more than thirty members of the Institute, comprising:
- (i) the President, the Past President, the President Elect and the Treasurer, _ex officio_ ;
- (ii) not more than twelve persons elected by members of the Institute registered within the regions (“regional members”); and
- (iii) not more than twenty persons elected by the members of the Institute (“national members”).
## _**RECRUITMENT AND TRAINING**_
The election of members of Council in the place of those retiring at any annual general meeting is made by a ballot, where necessary, of those entitled to vote. New members go through an induction process to familiarise them about their responsibilities and duties and periodic training sessions for all trustees are arranged as required.
## _**ORGANISATIONAL MANAGEMENT**_
Council meets at least quarterly to set overall strategy and policy and review performance.
Each Council member will also be heavily involved in the various standing committees. These committees are set up by Council and are given specific aims. They report back to Council at regular intervals and include:
- The Membership and Marketing Committee which is responsible for the creation and implementation of the Institute’s membership and marketing strategies. It is also the reporting committee for the local region and branch network.
- The Education and Professional Standards Committee which is responsible for matters relating to professional standards, education, training and professional development of members working in the profession.
- The Finance and Risk Committee which is responsible for monitoring the financial performance of the Institute, the performance of the Institute’s investments and the effectiveness of the Institute’s risk management processes and making recommendations to Council.
- The Audit Committee which seeks assurance from the external auditor that the accounts give a true and fair view of the financial performance and position and that the accounts comply with relevant accounting standards. The Audit Committee will also consider any issues raised by the auditors and the management’s response.
- The Remuneration Committee which is responsible for determining the Institute’s remuneration strategy and reviewing the terms and conditions of employment for the Chief Executive.
The Institute has a Chief Executive who is accountable directly to Council. The Institute’s staff carry out the detailed day-to-day work on behalf of Council and assist committees as necessary.
## _**RISK MANAGEMENT**_
Council has considered the major risks to which the Institute is exposed. The categories of risks identified were strategic risks, membership risks, governance risks, financial risks and operational risks. Council agreed that systems and procedures had been implemented to mitigate the risks which were identified.
Page 2
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Council Members’ Report (continued)**
## _**RISK MANAGEMENT (CONTINUED)**_
The principal risks identified by the charity are as follows:
## **Risk**
Government policy moves away from statutory regulation of the profession and national accreditation of laboratories for the four nations and crown dependencies.
Current CRM and website do not allow the Institute to update the member online self-service portal.
## **Mitigating actions**
- Continued engagement with HCPC and UK government to identify ongoing risk.
- Monitor progress of the review of the GMC register carefully.
- Regular meetings with HCPC and UKAS to shape future policy developments.
- Existing systems maintained to ensure continuity of service.
- Project undertaken to identify a replacement CRM and new supplier appointed.
- New CRM to link with other Institute digital platforms.
Failure to secure advertising revenue for the Biomedical Scientist publication results in the Institute funding the publication.
- Potential print and production cost savings explored.
- External independent advice sought on options.
- Funding options reviewed by F&RC.
## **Public Benefit Statement**
Council has complied with the duty in section 17(5) of the Charities Act 2011 and has referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing the Institute’s aims and objectives and in planning future activities. Council is satisfied that the Institute continues to meet the required public benefit test through its objectives and activities.
The Institute aims to promote and develop the role of biomedical science within healthcare to deliver the best possible service for patient care and safety. It does this by:
- Acting as an advocate for the biomedical science community with key stakeholders and policy makers to help ensure the high standards of the profession and patient safety are maintained.
- Developing and maintaining educational qualifications to enhance the skills, knowledge and career development of biomedical scientists within the profession.
- Providing opportunities for biomedical scientists to keep up to date with scientific developments through Institute publications and training events.
- Raising awareness of the importance of biomedical science in the provision of healthcare and the career opportunities in the profession.
- Supporting original research into scientific developments.
## **Investment Powers, Policy and Performance**
The investment powers are governed by the Institute’s Memorandum, which permits funds not immediately required for the purposes to be invested as the Council sees fit.
The Council’s policy is to achieve an agreed growth target in excess of inflation over the long term. The portfolio as a whole is managed to reduce the risk of negative returns in excess of 20%. Income generated is re-invested to assist with the long-term growth objective.
The Institute invests in companies whose activities are consistent with the charity’s values and demonstrate a commitment to stewardship and responsible and sustainable investment. An element of the portfolio is specifically invested in sectors and companies that are aligned with the values and expertise of the charity.
The Council establishes the investment strategy and takes advice from its investment advisors who manage the portfolio on a day to day basis. Performance is monitored by the Finance and Risk Committee and the period end position is reported in note 7 (a).
Page 3
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Council Members’ Report (continued)**
## **Objectives, Activities, Achievements and Performance**
The Institute of Biomedical Science (IBMS) is a registered charity and aims to promote and progress the role of biomedical science within healthcare to support the delivery of the best possible service for patient care and safety.
Each year it achieves this through publishing professional publications and guidance, running courses and seminars, organising scientific conferences (including the biennial IBMS Congress) and events, providing a platform to achieve higher-level qualifications, access to digital content and public engagement resources, hosting regional and branch events and through running discussion groups. The major achievements in the year are summarised below:
## **Supporting the profession and our members:**
- To recognise consistent, long and valuable service to the IBMS, we awarded three Life Memberships and one Honorary Fellowship.
- IBMS Chief Executive, David Wells, responded to a letter that was published in the Metro newspaper that stated that NHS laboratories were "overstaffed with unproductive people."
- Released a joint statement with The Royal College of Pathologists (RCPath) and British Association for Cytopathology (BAC) to guide the delivery of diagnostic cytopathology services across England.
- Alongside the RCPath we supported NHS England to produce their Transforming Histopathology in England plan.
- In response to NHS England’s Long-Term Workforce Plan the IBMS launched the IBMS Long Term Biomedical Scince Workforce Plan, a bold strategy for the UK to develop the biomedical scientist workforce to operate at the highest levels of practice through training, experience, and professional qualifications.
- Collaborating with the RCPath we produced an updated joint statement and accompanying practice and competency information on advanced roles in biomedical scientist reporting.
- Working with Microsoft we launched a white paper: Digital Pathology and Integrated Care Systems: Enabling highquality, equitable digital pathology services across networks, ICSs and nationally.
- Working with the RCPath and The Association for Laboratory Medicine (ALM) we issued a joint letter of concern to both the health secretary and shadow health secretary to highlight our concerns regarding the provision to patients of direct access to all test results.
- Following the government’s announced pay offer to nurses to resolve the national strike action, we issued a statement raising our concerns about an exclusive offer for a separate pay spine for nurses.
- After the Health and Care Professions Council (HCPC) announced that their annual registration fee was set to increase by 20% we issued a response to highlight our disappointment and to show our members that we have raised their concerns to the HCPC during their consultation.
- After a long period of no activity Kent and Reading branches in the southeast region and Tayside in Scotland are in the process of arranging meetings. Derby and Nottingham branch is also being re-established.
- To produce new national guidance on Point-of-Care Testing we collaborated with the RCPath and the ALM.
- To better support individuals from low- and medium-income countries to join the IBMS a new pricing structure for international members was introduced.
- Submitted nominations for, and promoted winners of, the Association of Healthcare Sciences Associate and Honorary Fellowships.
- Through our Equity, Diversity and Inclusion Working Group ensured that a diverse range of our members’ voices are heard.
- To improve our diversity and inclusion we signed the updated Science Council Declaration on Equity, Diversity and Inclusion. Published monthly articles in the IBMS membership magazine, held events, updated the membership EDI policy, created a policy to allow for the collection of sensitive data and supported national awareness events.
- To support our registration and specialist qualifications and training in the laboratories we held eight online training webinars which increased the number of active verifiers (from 510 to 651) and examiners (from 337 to 426).
- There were 28 accreditation review events of biomedical science degree courses, including courses at three new universities. This covered 56 undergraduate and 16 post graduate programmes.
- Six existing degree apprenticeship programmes were successfully re-accredited.
- In recognition of high academic achievement on an IBMS Accredited undergraduate degree course, 36 President’s Prize Awards were given to IBMS eStudent members who graduated and achieved academic distinctions.
- We implemented updated accreditation criteria aligned to the Quality Assurance Agency for Higher Education Subject Benchmark Statement (2023) for the accreditation of undergraduate and postgraduate degrees in biomedical science for 2023/24.
Page 4
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Council Members’ Report (continued)**
## **Objectives, Activities, Achievements and Performance (continued)**
## **Supporting the profession and our members (continued):**
- The number of professional and academic representatives who have been trained to complete degree accreditation events was increased.
- The Mary MacDonald Bursary was awarded to two winners in February enabling them to undertake the Certificate of Achievement (one for Part I and one for Part II).
- The Rapid Onsite Evaluation (ROSE) module Specialist Portfolio was launched (two portfolios issued to date).
- 518 IBMS laboratory training approval applications were processed to support colleagues to complete the Certificate of Achievement, Certificate of Competence and Specialist Diploma in laboratories around the UK this year.
- Several equivalence-route candidates (Certificate of Competence by Equivalence) and a candidate for the Certificate of Attainment (Clinical Scientist) route were successfully supported and assessed and have now registered with the HCPC.
- To support the increased number of applications for this qualification in 2023, several new professional assessors trained for the Certificate of Attainment (Clinical Scientist) route to registration.
- On 1[st] September, aligned with the updated HCPC standards of proficiency, Version 5.0 of the Registration Training Portfolio was updated and launched as a digital-only portfolio using the platform OneFile. All guidance documentation for the new version was updated and provided to members on the website as well as through a series of how-to presentations at IBMS Congress 2023.
- All four HCPC approved routes to registration as a biomedical scientist provided by the IBMS have been created as digital portfolios and are also hosted on OneFile.
- All guidance documentation for the Certificate of Competence by Equivalence was updated and aligned to the updated HCPC standards of proficiency and digital copies provided to members.
- 10 IBMS Support Hubs on a variety of themes were hosted in 2023, all are available as an open-access resource on the IBMS website and YouTube channel.
- As an approved HCPC education provider, the IBMS submitted HCPC Performance Review documentation in 2023. The HCPC panel concluded that we are performing well in all areas scrutinised.
## **Progressing the profession and the careers of our members**
- A highly successful IBMS Congress was held in September which achieved a record number of attendees and exhibitors.
- 13 presentations from IBMS Congress 2023 were recorded and promoted to members available for them to watch and record for their continuing professional development (CPD) records.
- The Jen Johnson Bursary ensured that 19 members received funding to attend IBMS Congress 2023.
- The annual two-day The Biomedical Scientist Live virtual event was held again for members to support their learning.
- In March we hosted a Covid Symposium webinar event to reflect on the profession’s contribution to the pandemic.
- Our routes to membership were reviewed and approved to include the Diploma of Expert Practice plus an MSc and 5 years relevant professional experience for admittance to the grade of Fellow.
- A 50% discount for Fellows who are or wish to become a Chartered Scientist was approved.
- We welcomed non biomedical scientists working in IT laboratories to membership in order to take the Certificate of Expert Practice.
- 260 candidates across the six IBMS Certificate of Expert Practice (CEP) qualifications passed. This was the largest number to pass in one year and included 17 candidates who passed the IBMS CEP in Laboratory Information Technology and Clinical Informatics, which ran for the first time in 2023.
- 42 candidates sat the Higher Specialist Diploma (HSD) in 2023 and 32 candidates passed, enabling them to upgrade to become a Fellow. Nine training events were delivered to anyone undertaking the qualification.
- 14 candidates sat the Stage C exam for the Advanced Specialist Diploma (ASD) in Histopathology Reporting exam and we launched the ASD in Bowel Screening Histopathology Reporting and ASD in Cervical Histopathology Reporting qualifications.
- 35 candidates sat the Diploma of Expert Practice (DEP) Histological Dissection exam in November 2023. A record 11 candidates sat the ASD in Histological Dissection (4 in breast pathology and 7 in Lower GI pathology) in November 2023.
- Health Education England provided funding training grants totalling over £350,000 to employers in England to support candidates in the IBMS Histopathology, Cytology, HSD and CEP qualifications.
Page 5
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Council Members’ Report (continued)**
## **Objectives, Activities, Achievements and Performance (continued)**
## **Progressing the profession and the careers of our members(continued):**
- Four online and one in-person Specialist Portfolio Train the Trainer webinars were held to assist laboratory trainers to support their candidates and to encourage members to become specialist portfolio examiners and to provide refresher training for existing examiners.
- There were two training events to train individuals to assist with IBMS laboratory training approval applications, this has resulted in 10 trained assessors and reduced the backlog of applications.
- The military specialist portfolio has been updated to fit the changing requirements of deployed military biomedical scientists and this has been approved by the education committee.
- Our virtual learning platform has been further developed to include online portfolios.
- To support the career progression of support staff via the Certificate of Achievement 167 portfolios and 150 certificates were issued.
- To support the HCPC registration of biomedical scientists we issued 1,273 registration training portfolios and 1,341 Certificates of Competence.
- Eight candidates were enrolled on the Certificate of Competence by Equivalence (Biomedical Scientist) route for 2023, their portfolio and viva assessments will be completed in 2023/24
- To support the career progression of biomedical scientists. 776 non-accredited degree assessments were processed. and 861 specialist portfolios and 379 Specialist Diplomas were issued.
- Through the IBMS CPD system, we validated CPD diplomas for 246 members.
- We welcomed 2,477 new joiners as IBMS members and supported 466 members to upgrade their membership.
## **Promoting the profession and the successes of our members**
- As part of a routes to registration campaign that promotes the IBMS routes to ‘Become a biomedical scientist’ through HCPC registration a logo for IBMS Accredited degrees was designed and trademarked.
- Four separate part-animated videos that cover each route to HCPC registration and a bespoke webpage, advertising and marketing materials were created to support the campaign to a wider audience.
- The children’s charity Harvey’s Gang was wound down by the trustees. The IBMS took over the management of the initiative, promoting the tours to the profession which led to a growth in the number of hospitals running the tours across the UK.
- Launched the latest in the series of Sample Journey videos for Healthcare Science Week 2023. The video follows the journey of a semen sample being processed through an andrology department.
- Staff and members attended the National School and College Leavers Festival 2023 and launched the IBMS virtual reality world – a Biomedical Science Space Lab, as well as showcasing the ‘Become a biomedical scientist’ campaign.
- Welsh language versions of the ‘Become a biomedical scientist’ marketing materials were created along with the Superlab II comic. IBMS members took part in the Cardiff Science Festival and annual National Eisteddfod cultural festival using the new materials.
- Black History Month was celebrated as we highlighted the contributions our black members make to biomedical science.
- The IBMS’s profile post-pandemic grew as it developed a policy and engagement capability at government level meeting MPs from across four nations, attending all party parliamentary group discussions and hosting a panel discussion at a political party conference focused on the impact of diagnostics and the biomedical science workforce.
- An event was held at the House of Lords on Biomedical Science Day to celebrate the profession and engage with stakeholders.
- The sixth annual Biomedical Science Day was held, it was the biggest celebration so far and campaigns were in the top 5 trends on social media all day and reached an audience of over four million people.
- IBMS members were supported to take part in public engagement events throughout the year including at national events for Healthcare Science Week and Biomedical Science Day, providing them with promotional materials and funding to highlight biomedical science to the public.
- Sponsored external national science awards – STEM for Britain and the Advancing Healthcare Awards ‘Biomedical Scientist of the Year’ award plus Leadership Awards for Northern Ireland and Wales.
- Sponsored a media fellowship placement to enable a member to attend and undertake a 3-week placement with a national media organisation.
Page 6
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Council Members’ Report (continued)**
## **Objectives, Activities, Achievements and Performance (continued)**
## **Promoting the profession and the successes of our members (continued):**
- The British Journal of Biomedical Science, an IBMS publication, launched 9 special issues that focused on research and the contribution our profession makes to healthcare. We also launched a prize to support biomedical scientists at the start of their research careers and published 29 papers.
- 50-year medals were awarded to 47 members to celebrate their membership of the Institute.
- 17 new Chartered Scientists, 8 Registered Scientists and 6 Registered Science Technicians were admitted to the Science Council registers.
## **Ensuring organisational robustness**
- Commissioned a project to identify a new customer relationship database (CRM) system that will enhance member experience and can be integrated with the new website and other business systems to increase self-service options for members. A preferred supplier has been identified and work will start in early 2024 to scope out our business requirements.
- Undertook technical systems enhancements for data protection and cyber security that included robust testing of the IBMS business continuity plans.
- Various training courses were arranged for managers to attend, including mental health awareness to support staff wellbeing.
The IBMS Council has identified a number of key performance indicators to help monitor the organisation’s performance. These include:
- Membership numbers – overall membership numbers increased by 239 or 1.2% from the previous year. The reduction in the number of Fellows was as expected. There was reduction in the number of associate members but growth in the Licentiate and Member grades.
- Educational activity - the number of registration and specialist portfolios issued increased year on year. The number of degree assessments was significantly higher. Turnaround times were broadly on target or ahead of target. There was a full programme of Institute exams in the year, and candidate numbers on the distance-learning qualifications continued to grow.
- Financial performance- the surplus on income and expenditure was higher than expected in 2023. The surplus on Congress exceeded expectations. Education income exceeded target but strategy expenditure significantly lower than planned. There was a positive return from the investment portfolio of £826,000 despite significant turbulence in the investment markets during the year.
- Staff turnover and sickness levels – sickness levels remained in line with expectations for an organisation of this size. Staff turnover was higher than expected, particularly in the education and membership teams. The job market remained very competitive during the year.
## **Financial Review**
The combined results of the Institute and its subsidiary are shown on pages 14 to 17 of the financial statements. The Institute is a non-profit making organisation and accordingly no dividends are proposed.
The Group Statement of Financial Activities on page 14 shows net income of £1,046,000, which included a gain on listed investments of £765,847. Funds are invested across a number of pooled funds to achieve a targeted total return and the year-end position is reported in note 7a. The investment portfolio generated a positive return of 7.8% after fees for the year. The turbulence in the financial markets from worldwide political and economic events continued during the year. The turbulence in the financial markets is expected to continue for some time.
Total income increased by 9% compared to the previous year. Income included the sales from Congress 2023 and HEE grant income (restricted funds) to cover the grants made to support candidates on some Institute qualifications. Income for portfolios, assessments and accreditations was 27% up on the prior year and income from qualifications was up 24%. Membership income was slightly lower than the previous year despite a small growth in membership numbers. This was due to the changes in member numbers in the different grades.
Page 7
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Council Members’ Report (continued)**
## **Financial Review (continued)**
Total expenditure increased by 20% compared to the previous year. This included the costs of Congress 2023 and the HEE grants paid to employers which were both higher than 2022. There were costs associated with supporting the publication of the Biomedical Scientist magazine, implementing a digital system to support the registration portfolio qualification and developing digital resources to promote the routes to registration.
The increase in funds for the year has been transferred to reserves.
IBMS (Professional Services) Ltd made a profit before tax of £661,695 (2022: profit £576,208). The profit was in line with the directors’ expectations as there was a Congress event during the year. The directors agreed to make a gift aid payment to the Institute in 2024 to reduce the corporation tax liability to £nil.
## **Grant-Making Policy**
The Education and Professional Standards Committee has delegated responsibility to agree the annual programme of research grants. It makes a detailed assessment of each application. Grants this year totalled £14,428 (2022: £15,376). All grants during the current and preceding year were made to individuals in order to further their biomedical research. The Committee administered the Mary Macdonald award which was awarded to individuals based on pre-determined criteria to give them the opportunity to attend Congress. Grants this year totalled £123 (2022: £882) as there was a Congress event in both years.
The Membership and Marketing Committee administer the Jen Johnson bursary which is awarded to individuals based on pre-determined criteria to give them the opportunity to attend Congress. Grants this year totalled £15,004 (2022: £14,593) as there was a Congress event in both years.
## **Remuneration Policy**
The Institute’s policy is to provide competitive rewards to attract and retain high performing individuals whose contribution will enhance member value while ensuring rewards remain appropriate and proportionate when compared to market practice. The Institute aims to position salaries at the median of comparator groups. Benchmarking is undertaken periodically and appropriate judgement is applied in evaluating market data. This policy has been agreed by the Remuneration Committee.
The Remuneration Committee is responsible for setting the salary of the Chief Executive. The salaries of the other key management personnel are set by the Chief Executive following consultation with the Officers.
## **Reserves Policy**
The Institute’s reserves policy focuses on the level of “free reserves”. Free reserves exclude the net book value of the Institute’s tangible fixed assets (primarily the property used and occupied at Coldbath Square), investment properties and any designated reserves. There are no restricted fund balances in this year or the prior year, but these would also be excluded, should there be any, in determining “free reserves”.
The reserves policy is reviewed regularly by Council on the basis of the financial impact of the current risks facing the Institute.
The Institute seeks to maintain free reserves to manage the risks to which it is exposed in the course of its business, including but not limited to safeguarding against fluctuations in its membership revenue.
Council considers that in order to meet these needs, and to operate effectively and be able to operate with minimum disruption, the Institute needs free reserves of approximately £5.5 million.
The Institute’s free reserves were £15.736 million at 31 December 2023 (2022: £14.287 million).
Council has agreed that if reserves fall by more than 10% below the target, it will consider what action is required to increase the level of reserves held.
Page 8
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Council Members’ Report (continued)**
## **Future Plans**
The Institute plans for a deficit of up to £100,000 on an ongoing basis i.e. excluding strategy costs, Congress and any significant one off costs. The deficit will be funded from the surplus generated by the biennial Congress event.
Future plans include providing better support, information and services for members through a variety of methods, including improved publications and greater online resources. For more information and a detailed review of future plans, see the Institute’s strategy and the Institute’s Members’ Report which are both available on the website.
## **Council Members’ Accounting and Reporting Responsibilities**
The Council members (who are also directors of the Institute of Biomedical Science for the purposes of company law) are responsible for preparing the Council’s report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
Company law requires the Council members to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and group as at the balance sheet date, and of the charitable company and group’s incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the trustees are required to:
- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.
The Council members are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's and the group’s transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the charitable company's Memorandum and Articles of Association. They are also responsible for safeguarding the assets of the charitable company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The Council Members are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.
The following statements have been affirmed by each of the Council Members of the charitable company:
- so far as each Council member is aware, there is no relevant audit information (that is, information needed by the company's auditors in connection with preparing their report) of which the company's auditors are unaware; and
- each Council member has taken all the steps that they ought to have taken as a Council member in order to make themselves aware of any relevant audit information and to establish that the charitable company's auditors are aware of that information.
Page 9
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Council Members’ Report (continued)**
## **Auditors**
Haysmacintyre LLP were re-appointed as auditors during the year and offer themselves for re-appointment at the forthcoming Annual General Meeting.
## **Small Company Exemptions**
This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies and groups.
Approved by Council on 19 April 2024 and signed on their behalf by:
J Andrew President
N Coles Treasurer
D Wells Chief Executive and Company Secretary
Page 10
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Independent Auditors’ Report to the Members of the Institute of Biomedical Science**
## **Opinion**
We have audited the financial statements of the Institute of Biomedical Science for the year ended 31 December 2023 which comprise of the Consolidated Statement of Financial Activities, Consolidated Balance Sheet and the Charity Balance Sheet, the Consolidated Statement of Cash flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
## In our opinion, the financial statements:
- give a true and fair view of the state of the group’s and of the parent charitable company’s affairs as at 31 December 2023 and of the group’s and parent charitable company’s net movement in funds, including the income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.
## **Basis for opinion**
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Financial Reporting Council’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
## **Conclusions relating to going concern**
In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.
## **Other information**
The trustees are responsible for the other information. The other information comprises the information included in the Council Members’ Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.
## **Opinions on other matters prescribed by the Companies Act 2006**
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Council Members’ Report (which incorporates the strategic report and the directors’ report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors’ report included in the Council Members’ Report have been prepared in accordance with applicable legal requirements.
Page 11
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Independent Auditors’ Report to the Members of the Institute of Biomedical Science (continued)**
## **Matters on which we are required to report by exception**
In the light of the knowledge and understanding of the group and the parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Council Members’ Report (which incorporates the strategic report and the directors’ report).
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees’ remuneration specified by law are not made;
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies’ regime and take advantage of the small companies’ exemptions in preparing the trustees’ report and from the requirement to prepare a strategic report.
## **Responsibilities of trustees for the financial statements**
As explained more fully in the trustees’ responsibilities statement set out on page 9, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the trustees are responsible for assessing the group’s and the parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group charitable company or to cease operations, or have no realistic alternative but to do so.
## **Auditor’s responsibilities for the audit of the financial statements**
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
Based on our understanding of the group and the environment in which it operates, we identified that the principal risks of non-compliance with laws and regulations related to GDPR and Health and Safety legislation, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Companies Act 2006, the Charities Act 2011, income tax, payroll tax and sales tax.
Page 12
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Independent Auditors’ Report to the Members of the Institute of Biomedical Science (continued)**
We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to posting inappropriate journal entries to revenue and management bias in accounting estimates. Audit procedures performed by the engagement team included:
- Inspecting correspondence with regulators and tax authorities;
- Discussions with management including consideration of known or suspected instances of non-compliance with laws and regulation and fraud;
- Reviewing the controls and procedures of the charitable company to ensure these were in place throughout the year, including during the continued Covid-19 remote working period
- Evaluating management’s controls designed to prevent and detect irregularities;
- Identifying and testing journals, in particular journal entries posted with unusual account combinations, postings by unusual users or with unusual descriptions; and
- Challenging assumptions and judgements made by management in their critical accounting estimates
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.
A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.
## **Use of Audit Report**
This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.
**----- Start of picture text -----**
………………………………………..
**----- End of picture text -----**
_Kathryn Burton (Senior statutory auditor) for and on behalf of Haysmacintyre LLP, Statutory Auditor_
_10 Queen Street Place London EC4R 1AG_
> _Date:_ 23rd April 2024
Page 13
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Consolidated Statement of Financial Activities for the Year Ended 31 December 2023**
## **(Incorporating the Income and Expenditure Account)**
|**Notes**
**Income from:**
Charitable activities
Subscriptions
Qualifications
Portfolios, assessments and accreditations
Publications
Regions, branches and discussion groups
2
Other income
Congress and other trading activities
7c
Investments
Listed investment income
Property rental
Bank interest
**Total Income**
**Expenditure on:**
Raising Funds
Congress and other trading activities
Investment management fees
Charitable activities
Education, qualifications and registration
3
Publications
3
Regions, branches and discussion groups
2,3
Member events, representation and benefits
3
Grants and prizes
**Total Expenditure**
Net gains / (losses) on investments
**Net income / (expenditure)**
**Other recognised gains / (losses)**
Loss on revaluation of investment property
**NET MOVEMENT IN FUNDS FOR THE YEAR**
Total funds brought forward
**Total funds carried forward**
13,14|**Unrestricted**
**Funds**
**Restricted**
**Funds**
**2023**
**£**
**2023**
**£**
2,380,586
-
395,383
384,214
476,927
-
1,900
-
16,073
-
2,449
-
1,895,041
-
164,221
-
62,981
-
130,501
-|**Total**
**2023**
**£**
2,380,586
779,597
476,927
1,900
16,073
2,449
1,895,041
164,221
62,981
130,501
5,910,276
1,340,958
81,032
1,972,430
222,210
116,597
1,559,448
37,448
5,330,123
765,847
1,346,000
(300,000)
1,046,000
16,755,848
17,801,848|**Total**
**2022**
**£**
2,390,123
629,775
373,983
6,671
121,031
2,110
1,600,093
196,220
63,107
29,361|
|---|---|---|---|
||5,526,062
384,214||5,412,474|
||1,340,958
-
81,032
-
1,588,216
384,214
222,210
-
116,597
-
1,559,448
-
37,448
-||1,120,784
79,489
1,656,514
109,312
191,134
1,232,172
38,043|
||4,945,909
384,214||4,427,448|
||765,847
-||(1,310,233)|
||1,346,000
-
(300,000)
-||(325,207)
-|
||1,046,000
-
16,755,848
-||(325,207)
17,081,055|
||17,801,848
-||16,755,848|
All activities are continuing and there are no other recognised gains and losses other than those recognised above.
A comparative Statement of Financial Activity can be found in Note 20
A separate Statement of Financial Activities for the charity itself is not presented because the charity has taken advantage of the exemptions afforded by section 408 of the Companies Act 2006 and SORP (FRS102) 2019.
The notes on pages 18 to 32 form part of these financial statements.
Page 14
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Consolidated Balance Sheet as at 31 December 2023**
|**Notes**
**Fixed Assets**
Tangible assets
6
Listed investments
7a
Investment property
8
**Current Assets**
Stock
Debtors
9
Listed Investments – Money Market Deposits
7b
Cash at bank and in hand
**Creditors:**amounts falling due within one year
10
**Net Current Assets**
**Total assets less current liabilities**
**Net Assets**
**Unrestricted Funds**
Accumulated fund
Designated fund
Listed investment revaluation reserve
Investment property revaluation reserve
12,13|**2023**
**£**
1,179,287
11,425,990
850,000
13,455,277
356
470,445
1,023,372
4,722,030
6,216,203
(1,869,632)
4,346,571
17,801,848
17,801,848
16,222,143
36,992
1,118,180
424,533
17,801,848|**2022**
**£**
1,267,207
10,600,327
1,150,000
13,017,534
975
798,931
-
4,829,540
5,629,446
(1,891,132)
3,738,314
16,755,848|
|---|---|---|
|||16,755,848|
|||14,996,897
51,996
982,422
724,533
16,755,848|
Approved and authorised for issue by Council on 19 April 2024 and signed on their behalf by:
J Andrew N Coles President Treasurer
The notes on pages 18 to 32 form part of these financial statements.
Page 15
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Charity Balance Sheet as at 31 December 2023**
|**Notes**
**Fixed Assets**
Tangible assets
6
Listed investments
7a
Investment property
8
**Current Assets**
Stock
Debtors
9
Listed Investments – Money Market Deposits
7b
Cash at bank and in hand
**Creditors:**amounts falling due within one year
10
**Net Current Assets**
**Total assets less current liabilities**
**Net Assets**
**Unrestricted Funds**
Accumulated fund
Designated fund
Listed investment revaluation reserve
Investment property revaluation reserve
12|**2023**
**£**
1,179,287
11,426,990
850,000
13,456,277
356
461,945
1,023,372
3,397,268
4,882,941
(1,520,245)
3,362,696
16,818,973
16,818,973
15,239,268
36,992
1,118,180
424,533
16,818,973|**2022**
**£**
1,267,207
10,601,327
1,150,000
13,018,534
975
544,223
-
3,876,888
4,422,086
(1,514,662)
2,907,424
15,925,958|
|---|---|---|
|||15,925,958|
|||14,167,007
51,996
982,422
724,533
15,925,958|
The net movement in funds for the year for the charitable company, excluding the subsidiary, was a surplus of £893,014 (2022: deficit £901,414).
Approved by Council and authorised for issue on 19 April 2024 and signed on their behalf by:
J Andrew N Coles President Treasurer
The notes on pages 18 to 32 form part of these financial statements.
Page 16
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **Consolidated Statement of Cash Flows for the Year Ended 31 December 2023**
|Notes
**Reconciliation of net income / (expenditure) to cash flow from**
**operating activities**
Net income / (expenditure) for the year (as per Statement of
Financial Activities)
_Adjustments for:_
Depreciation of property, plant and equipment
6
(Gains) / losses on investments
Loss / (profit) on sale of fixed asset
Listed investment income and bank interest
Property rental
Decrease / (increase) in stock
Decrease / (increase) in debtors
9
(Decrease) / increase in creditors
10
**Net cash provided by operating activities**
**Cash flows from investing activities**
Listed investment income and bank interest
Property rental
Purchase of property, plant and equipment
6
Purchase of investments
Disposal of investments
(Increase) / decrease in cash in investment portfolio
(Increase) / decrease in cash in money market deposits
**Net cash (used in) / provided by investing activities**
**Change in cash and cash equivalents in the reporting period**
Cash and cash equivalents at start of year
**Cash and cash equivalents at end of year**
**Components of cash and cash equivalents**
Cash at bank and in hand
Short term deposits
**Analysis of change in net debt**
There are no debts held, the net debt relates only to cash and cash equivalents
Cash and cash equivalents at start of year
Cash flows
Cash and cash equivalents at end of year||**2023**
**£**
1,346,000
118,878
(765,847)
-
(294,722)
(62,981)
619
328,486
(21,500)
648,933
294,722
62,981
(30,958)
(7,999,327)
8,016,126
(101,632)
(998,355)
(756,443)
(107,510)
4,829,540
4,722,030
1,703,032
3,018,998
4,722,030
**2023**
**£**
4,829,540
(107,510)
4,722,030|||**2022**
**£**
(325,207)
115,901
1,310,233
2,495
(225,581)
(63,107)
-
(100,914)
(882,080)|
|---|---|---|---|---|---|
||||||(168,260)|
||||||225,581
63,107
(90,440)
(7,310,732)
6,730,185
463,817
-|
||||||81,518|
||||||(86,742)
4,916,282
4,829,540|
||||||1,810,769
3,018,771|
||||||4,829,540|
||||||**2022**
**£**
4,916,282
(86,742)
4,829,540|
|||||||
The notes on pages 18 to 32 form part of these financial statements.
Page 17
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023**
## **1 - Accounting Policies**
## **Statutory Information**
The Institute of Biomedical Science is a private company, limited by guarantee, domiciled in England and Wales, registration number 377268. It is also a charity registered with the Charity Commission for England and Wales, number 261926. The registered office is 12, Coldbath Square, London EC1R 5HL.
The Institute is a charitable company limited by the guarantee of its members to a maximum of £1 per member on winding up.
## **Statement of compliance**
The financial statements are prepared under the historical cost convention as modified to include the revaluation of investments at fair value. The format of the financial statements has been presented to comply with the Companies Act 2006, FRS102 The Financial Reporting Standard applicable in the UK and Ireland and the Statement of Recommended Practice Accounting and Reporting by Charities (SORP 2019).
The financial statements are presented in sterling and reflect the results which are all from continuing activities.
The Institute is a Public Benefit Entity as defined by FRS102.
## **Going concern**
In assessing the Institute's ability to continue as a going concern, the Council members have considered whether there are any material uncertainties affecting the Institute’s ability to continue as a going concern, the organisation’s liquidity position and reviewed cash flow forecasts for the foreseeable future. In addition to its cash reserves, it has an investment portfolio to draw upon and two properties, with no external debt or security.
The Institute has prepared a cash flow forecast covering at least twelve months from the date of signing the accounts. The forecast indicates that the Institute will have sufficient cash reserves to meet its obligations without the need to draw on its investment portfolio.
The Council members continue to adopt the going concern basis in preparing the accounts.
## **Significant judgements and sources of estimation uncertainty**
The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Charity’s accounting policies. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Although these estimates are based on management’s best knowledge of the amount, events or actions, actual results may ultimately differ from those estimates. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects current and future periods. The Council consider the following items to be areas subject to estimation and judgement:
_Depreciation_ : - the useful economic lives of tangible fixed assets are based on management’s judgement and experience. When management identifies that the actual useful economic lives differ materially from the estimates used to calculate depreciation, that charge is adjusted retrospectively. Although tangible fixed assets are significant, variances between actual and estimated useful economic lives will not have a material impact on the operating results.
_Investment property_ : - The principal assumptions used to value the investment property are those as set out in note 8.
In the view of the Council members, no assumptions concerning the future or estimation uncertainty affecting assets or liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year.
Page 18
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **1 - Accounting Policies (continued)**
## **Basis of consolidation**
These financial statements consolidate the results of the Institute and its wholly owned subsidiary, Institute of Biomedical Science (Professional Services) Limited, on a line by line basis. A separate Statement of Financial Activities for the charity itself is not presented because the charity has taken advantage of the exemptions afforded by section 408 of the Companies Act 2006 and SORP (FRS102) 2019. The charity’s income for the year amounted to £4,593,027 (2022: £3,894,485). The charity’s net movement in funds for the year was an increase of £893,014 (2022: reduction £901,414).
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the Group’s financial statements.
## **Fund accounting**
Funds received for a specified purpose are shown as restricted income in the Statement of Financial Activities. Any such income not spent at the year-end is shown as a restricted fund in the balance sheet.
The Institute has unrestricted funds made up of membership subscriptions, income from educational activities and other income received or generated for its charitable purposes. These are available for trustees to utilise at their discretion and in line with the charity’s objects.
Unrestricted funds which the trustees have agreed to set aside for a specific purpose are shown as designated funds on the balance sheet.
## **Income**
All income is recognised once the Institute is entitled to the income, it is probable that the income will be received and can be quantified with reasonable accuracy.
Subscriptions comprise approved membership applications for the various categories of membership. Subscriptions received which relate to a future financial period are included in the balance sheet as deferred income.
Qualifications comprise the charge made for courses and qualifications provided by the Institute. Any income relating to courses or exam sittings occurring after the balance sheet date is included in the balance sheet as deferred income.
Registrations comprise the fees for accrediting an individual member’s portfolio of experience and the fees for the accrediting of biomedical science courses run by educational institutions. The income is recognised at the point of registration.
Regions and branches comprise the income generated locally (mainly from local training events) by the regions and branches to run discussion groups and meetings.
Property rental comprises the income received from renting out the building at No5 Coldbath Square. Income which has been invoiced but relates to a future financial period is included in the balance sheet as deferred income.
Trading activities comprise the income generated by IBMS (Professional Services) Ltd. It consists of income from running events (mainly Congress, a biennial event), providing secretarial support to other organisations and hire of meeting room facilities. Income received for events which are taking place after the balance sheet date is included in the balance sheet as deferred income.
Interest and investment income is recognised on a receivable basis.
## **Expenditure**
Expenditure is included on an accruals basis where there is a legal or constructive obligation to make a payment to a third party and the amount can be measured reliably. Expenditure is either directly attributed to a cost category, or apportioned on a basis consistent with the use of the resources.
Page 19
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **1 - Accounting Policies (continued)**
## **Expenditure (continued)**
Expenditure on charitable activities includes the cost of delivering education and other services to members for the benefit of the profession along with the associated support costs.
Expenditure on trading activities comprises the costs incurred by IBMS (Professional Services Ltd) and allocated support costs.
Support costs comprise the costs which cannot be directly attributed to a particular activity in the Statement of Financial Activity and include governance costs. Support costs are apportioned between the various activities according to the estimated usage of staff resource.
## **Grants**
Grants payable are charged in the year when the offer is conveyed to the recipient except where the offer is conditional and such grants are recognised as expenditure when the conditions have been met.
## **Listed investments**
Listed investments are shown at their fair value at the balance sheet date. Any increase or decrease in value is reflected in the Statement of Financial Activities.
## **Investment property**
Investment properties are disclosed at their fair market value at the balance sheet date based on an arm’s length transaction. Any increase or decrease in value is reflected in the Statement of Financial Activities.
A full valuation is undertaken every three years. The valuation is reviewed annually in the intervening years.
## **Tangible fixed assets and depreciation**
Assets with a useful economic life of more than one year and a value of over £500 are capitalised.
Tangible fixed assets have been depreciated so as to write assets off over their estimated useful lives at the following rates:
Freehold property: 2% per annum on a straight line basis Furniture, fixtures and fittings: 10% per annum on a straight line basis Computers: 20% to 33.33% per annum on a straight line basis Assets under construction: Nil depreciation until assets are ready for use
## **Pension schemes**
The Institute operated two defined contribution (DC) pension schemes during the year. See note 14.
The cost of the DC schemes is charged to the Statement of Financial Activities is equal to the Institute’s contribution payable to the schemes during the year.
The Defined Benefit scheme was wound up on 17 May 2021.
Page 20
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **1 - Accounting Policies (continued)**
## **Short term benefits**
Short term benefits, including holiday pay, are recognised as an expense in the period in which the service is received.
## **Employee termination benefits**
Termination benefits are accounted for on an accruals basis and in accordance with FRS 102.
## **Holiday pay accrual**
A liability is recognised to the extent of any unused holiday pay entitlement which has accrued at the balance sheet date and carried forward to future periods. This is measured at the undiscounted salary cost of the future entitlement and accrued at the balance sheet date.
## **Taxation**
Tax is provided on the taxable profits retained in the trading subsidiary.
## **Gift Aid**
The Institute of Biomedical Science (Professional Services) Ltd donates the taxable profit arising from its trading activity to the parent entity. The donation is recognised when paid or there is a legal obligation to make the payment.
## **Financial instruments**
Basic financial instruments are initially recognised at transaction value and subsequently measured at amortised cost with the exception of investments which are held at fair value. Financial assets held at amortised cost comprise cash at bank and in hand, trade and fee debtors, staff loans, other debtors, prepayments and accrued income and amounts owed by group undertakings. A specific provision is made for debts for which recoverability is in doubt. Cash and cash equivalents are defined as all cash held in instant access bank accounts and used as working capital. Financial liabilities held at amortised cost comprise deposits, fees in advance, trade creditors, other creditors and amounts owed to group undertakings.
## **Stock**
The value of medals held in stock to recognise members’ long service is stated at the lower of cost and their net realisable value.
## **Debtors**
Trade and other debtors are recognised at the settlement amount due for the provision of services delivered. Prepayments are recognised at the amount prepaid or the amount paid in advance.
## **Creditors**
Creditors are recognised where the institute has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured reliably. Amounts are recognised at their settlement amount.
## **Cash and cash equivalents**
Cash and cash equivalents include cash at bank and in hand and highly liquid interest-bearing securities with maturities of three months or less.
## **Irrecoverable VAT**
Irrecoverable VAT is charged to the Income and Expenditure account for the period to which it relates.
## **2 – Regions, Branches and Discussion Groups**
Regions, branches and discussion groups run activities that raise money locally and incur costs. Regions and branches were allocated a budget for their activity for the year. The balances remaining in bank accounts for discussion groups at the year-end of £246,693 (2022: £231,339) are included in the balance sheet. The costs include an apportionment of support costs (note 3) based on an assessment of staff resources used.
Page 21
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **3 - Total Expenditure**
|Trading activities
Investment management fees
Education, qualifications and registration
Publications
Regions, branches & discussion groups
Membership events, representation and
benefits
Grants & prizes
Total Expenditure|**Direct costs**
**£**
1,268,942
81,032
1,371,675
208,271
95,689
1,104,583
37,448
4,167,640|**Support costs**
**£**
72,016
-
600,755
13,939
20,908
454,865
-
1,162,483|**Total 2023**
**£**
1,340,958
81,032
1,972,430
222,210
116,597
1,559,448
37,448|
|---|---|---|---|
||||5,330,123|
Grants made during the current year totalled £29,555 to 24 individuals. In 2022 they totalled £30,851 to 27 individuals.
|Trading activities
Investment management fees
Education, qualifications and registration
Publications
Regions, branches & discussion groups
Membership events, representation and
benefits
Grants & prizes
Total Expenditure
**Support Costs**
People costs
Office running costs
IT & website
Irrecoverable VAT
Depreciation
Other costs
Governance
Council and committees
Audit|**Direct costs**
**£**
1,039,827
79,489
1,128,992
93,643
167,630
812,767
38,043
3,360,391||**Support costs**
**£**
80,957
-
527,522
15,669
23,504
419,405
-
1,067,057
**2023**
**£**
529,949
181,437
183,339
46,426
118,878
46,035
38,619
17,800
1,162,483||**Total 2022**
**£**
1,120,784
79,489
1,656,514
109,312
191,134
1,232,172
38,043|
|---|---|---|---|---|---|
||||||4,427,448|
||||||**2022**
**£**
482,872
146,151
146,322
66,862
115,901
50,136
42,563
16,250
1,067,057|
|||||||
Page 22
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **4 - Staff Costs**
|Salaries and wages
Social security
Employer pension contributions – DC schemes
Temporary staff
Life assurance
Staff expenses
Recruitment and training
The average number of employees in the period was:|**2023**
**£**
1,504,651
165,954
123,163
133,768
5,086
11,754
27,501
1,971,877
32|**2022**
**£**
1,280,653
149,748
105,005
170,089
4,801
8,861
43,198|
|---|---|---|
|||1,762,355|
|||27|
The number of staff whose annual emoluments in the period fell within the following bands were:
|£60,000|to|£70,000|3|-|
|---|---|---|---|---|
|£70,000|to|£80,000|1|2|
|£80,000|to|£90,000|3|1|
|£130,000|to|£140,000|1|1|
The Council consider the key management personnel for the Institute to be themselves, the Chief Executive, Deputy Chief Executive and the four executive team heads. The remuneration and benefits (included above) received by the key management personnel in employment during the year was £643,300 (2022: £616,2221).
None of the Council members received any emoluments or benefits from the Institute during the period for undertaking the role. Total costs of travel, accommodation and out of pocket expenses incurred during the period on the Institute’s business by 21 Council members (2022: 22 Council members) amounted to £32,999 (2022: £29,932).
## **5 – Net Income for the Year**
This is stated after charging:
|his is stated after charging:|||
|---|---|---|
||**2023**|**2022**|
||**£**|**£**|
|Auditors remuneration:|||
|Audit fee for the group (excluding VAT)|23,500|21,450|
|Other services (excluding VAT)|3,800|3,450|
|Depreciation|118,878|115,901|
|Operating leases|2,932|2,325|
Page 23
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **6 - Tangible Fixed Assets**
|**Group and Charity**
**Freehold**
**Property**
**£**
**Cost**
At 1 January 2023
800,000
Additions
-
Disposals
-
At 31 December 2023
800,000
**Depreciation**
At 1 January 2023
57,333
Charge for the year
16,000
Disposals
-
At 31 December 2023
73,333
**Net Book Value**
At 31 December 2023
726,667
At 31 December 2022
742,667
**7a – Listed and Unlisted Investments**
**2023**
**£**
Fixed Asset Listed investments -
valuation
As at 1 January
10,372,818
Additions
7,999,327
Disposals
(8,016,126)
Realised (losses) / gains
(42,968)
Unrealised gains / (losses)
783,798
At 31 December
11,096,849
Investment in subsidiary
-
Cash held as investments at
period end
329,141
Total investments
11,425,990|**Furniture,**
**Fixtures &**
**Fittings**
**£**
634,824
1,235
-
636,059
203,116
63,351
-
266,467
369,592
431,708
**Group**
**2022**
**£**
11,102,504
7,310,732
(6,730,185)
(684,127)
(626,106)
10,372,818
-
227,509
10,600,327||**Computers**
**Total**
**£**
**£**
366,201
1,801,025
29,723
30,958
(1,474)
(1,474)
394,450
1,830,509
273,369
533,818
39,527
118,878
(1,474)
(1,474)
311,422
651,222
83,028
1,179,287
92,832
1,267,207
**Charity**
**2023**
**£**
**2022**
**£**
10,372,818
11,102,504
7,999,327
7,310,732
(8,016,126)
(6,730,185)
(42,968)
(684,127)
783,798
(626,106)
11,096,849
10,372,818
1,000
1,000
329,141
227,509
11,426,990
10,601,327|**Computers**
**Total**
**£**
**£**
366,201
1,801,025
29,723
30,958
(1,474)
(1,474)
394,450
1,830,509
273,369
533,818
39,527
118,878
(1,474)
(1,474)
311,422
651,222
83,028
1,179,287
92,832
1,267,207
**Charity**
**2023**
**£**
**2022**
**£**
10,372,818
11,102,504
7,999,327
7,310,732
(8,016,126)
(6,730,185)
(42,968)
(684,127)
783,798
(626,106)
11,096,849
10,372,818
1,000
1,000
329,141
227,509
11,426,990
10,601,327|**Total**
**£**
1,801,025
30,958
(1,474)|
|---|---|---|---|---|---|
||||||1,830,509|
||||||533,818
118,878
(1,474)|
||||||651,222|
||||||1,179,287|
||||||1,267,207|
|||||10,372,818
1,000
227,509||
|||||10,601,327||
Page 24
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **7a – Listed and Unlisted Investments (continued)**
The market values of the group’s fixed asset listed investments on the UK Stock exchange were:
|Managed funds – UK equities
Managed funds – overseas equities
Managed funds – alternative strategies
Managed funds – fixed interest securities
Managed funds – multi-asset funds
Managed funds – commodities
Sub-total
Cash held in the investment portfolio|**2023**
**£**
103,435
7,165,131
1,485,399
1,990,703
336,733
15,448
11,096,849
329,141
11,425,990|**2022**
**£**
1,410,271
6,384,746
893,610
1,684,191
-
-|
|---|---|---|
|||10,372,818
227,509|
|||10,600,327|
The historical cost of the fixed asset listed investments was £10,370,211 (2022: £10,329,957).
## **7b Current Asset Listed Investments**
|**Group and Charity**
Valuation
As at 1 January
Additions
Unrealised gains / (losses)
Sub-total
Cash held as investment at period end
Total investment|**2023**
**£**
-
997,000
25,017
1,022,017
1,355
1,023,372|**2022**
**£**
-
-
-|
|---|---|---|
|||-
-|
|||-|
The market value of the current asset listed investments for the group and charity were:
|Managed funds – money market deposits
Sub-total
Cash held in the investment portfolio
ther investments in the charitable company accounts were:
Unlisted investments comprising of:
Institute of Biomedical Science (Professional Services) Ltd
1,000 Ordinary shares of £1 each|**2023**
**£**
1,022,017
1,022,017
1,355
1,023,372
**2023**
**£**
1,000|**2022**
**£**
-
-
-
-
**2022**
**£**
1,000|
|---|---|---|
Other investments in the charitable company accounts were:
## **7c - Subsidiary**
The investment in the Institute of Biomedical Science (Professional Services) Limited represents 100% of that Company’s ordinary share capital and is therefore a subsidiary undertaking. The subsidiary is registered in England and Wales and the registered office is 12, Coldbath square, London EC1R 5HL.
Page 25
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **7c – Subsidiary (continued)**
The Institute of Biomedical Science (Professional Services) Limited made a qualifying charitable donation of £508,710 (2022: £nil) to its parent company, the Institute of Biomedical Science. The assets, liabilities and funds of the subsidiary were:
|Assets
Liabilities
Representing:
Share Capital
Profit and Loss account
etails of the subsidiary’s profit and loss accounts are as follows:
Turnover
Cost of sales
Gross profit / (loss)
Interest receivable
Administrative expenses
Corporation Tax
Gift aid donation to parent undertaking
Movement on profit and loss account for the year|**2023**
**£**
1,451,117
(467,242)
983,875
1,000
982,875
983,875
**2023**
**£**
1,895,041
(1,235,497)
659,544
16,488
(14,337)
661,695
-
(508,710)
152,985|**2022**
**£**
1,232,633
(401,743)
830,890
1,000
829,890
830,890
**2022**
**£**
1,600,093
(1,013,093)
587,000
1,865
(12,657)
576,208
-
-
576,208|
|---|---|---|
Details of the subsidiary’s profit and loss accounts are as follows:
This subsidiary has been formed to deal with activities that are regarded as trading. Such activities include receiving income from trade exhibitions.
## **8 – Investment property – No5 Coldbath Square**
|**Group and Charity**
As at 1 January
Unrealised (loss) / gains
At 31 December|**2023**
**£**
1,150,000
(300,000)
850,000|**2022**
**£**
1,150,000
-|
|---|---|---|
|||1,150,000|
The property was independently valued in December 2023 in accordance with the appropriate practice statement set out in the RICS Appraisal and Valuation Manual. The person who undertook the valuation holds a recognised and relevant professional qualification and has knowledge of properties in the area.
The property was valued at market value, which is defined as “the estimated amount for which a property should exchange on the date of the Valuation between a willing buyer and a willing seller in an arm’s length transaction, after proper marketing wherein the parties had acted knowledgeably, prudently and without compulsion”.
The next full valuation will be undertaken in December 2026. In the interim, the value will be reviewed and updated by an independent property professional.
Page 26
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **9 – Debtors**
|Trade debtors
Prepayments
Taxation and social security
Accrued income
Amounts owed from group undertakings
Total|**2023**
**Group**
**£**
**Charity**
**£**
101,899
93,399
216,675
216,675
145,590
145,590
6,281
6,281
-
-
470,445
461,945|**2022**
**Group**
**£**
**Charity**
**£**
489,507
363,295
299,427
145,658
-
-
9,997
9,997
-
25,273
798,931
544,223|**2022**
**Group**
**£**
**Charity**
**£**
489,507
363,295
299,427
145,658
-
-
9,997
9,997
-
25,273
798,931
544,223|
|---|---|---|---|
||||544,223|
Intercompany balances arise in the normal course of trading and as a result of the group VAT registration.
## **10 – Creditors**
## **Amounts Falling Due Within One Year**
|Deferred income
Trade creditors
Taxation and social security costs
Accruals
Other creditors
Amounts owed to group undertakings|**Group**
**£**
1,136,266
512,924
51,372
129,859
39,211
-
1,869,632|**2023**
**Charity**
**£**
1,136,266
56,179
51,372
120,359
38,214
117,855
1,520,245|**2022**
**Group**
**£**
**Charity**
**£**
1,594,256
1,238,607
84,889
73,118
45,075
45,075
121,089
112,439
45,823
45,423
-
-
1,891,132
1,514,662|**2022**
**Group**
**£**
**Charity**
**£**
1,594,256
1,238,607
84,889
73,118
45,075
45,075
121,089
112,439
45,823
45,423
-
-
1,891,132
1,514,662|
|---|---|---|---|---|
|||||1,514,662|
## **11 – Deferred Income**
|**Balance brought forward**
Amounts released to SOFA in current
year
Amounts deferred in the current year
**Balance carried forward**|**Group**
**£**
1,594,256
(1,260,623)
802,633
1,136,266|**2023**
**Charity**
**£**
1,238,607
(904,974)
802,633
1,136,266|**2022**
**Group**
**£**
**Charity**
**£**
2,388,573
1,172,898
(1,917,808)
(702,133)
1,123,491
767,842
1,594,256
1,238,607|**2022**
**Group**
**£**
**Charity**
**£**
2,388,573
1,172,898
(1,917,808)
(702,133)
1,123,491
767,842
1,594,256
1,238,607|
|---|---|---|---|---|
|||||1,238,607|
Deferred income includes amounts received for membership subscriptions, qualifications and Congress which relate to a future accounting period. The balance also includes funds received from Health Education England for the histopathology reporting project and advanced practice project which have not yet been recognised as income.
Page 27
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **12 - Reconciliation of Movements in Funds**
|**Group**
**Restricted Funds**
HEE Histopathology project
Total restricted funds
**Unrestricted Funds**
Designated Funds:
Jen Johnson Bursary
Total designated funds
Accumulated funds
Listed investment
revaluation reserve
Investment property
revaluation reserve
Total unrestricted funds
**Group**
**Restricted Funds**
HEE Histopathology project
Total restricted funds
**Unrestricted Funds**
Designated Funds:
Jen Johnson Bursary
Total designated funds
Accumulated funds
Listed investment
revaluation reserve
Investment property
revaluation reserve
Total unrestricted funds|**At**
**01/01/2023**
**Income**
**Expenditure**
**Net gains /**
**(losses)**
**Transfers**
**At**
**31/12/2023**
**£**
**£**
**£**
**£**
**£**
**£**
-
384214
(384,214)
-
-
-|
|---|---|
||-
384,214
(384,214)
-
-
-|
||51,996
-
(15,004)
-
-
36,992|
||51,996
-
(15,004)
-
-
36,992
14,996,897
5,526,062
(4,930,905)
(42,968)
673,057
16,222,143
982,422
-
-
808,815
(673,057)
1,118,180
724,533
-
-
(300,000)
-
424,533|
||16,755,848
5,526,062
(4,945,909)
465,847
-
17,801,848|
|||
||16,755,848
5,910,276
(5,330,123)
465,847
-
17,801,848|
||**At**
**01/01/2022**
**Income**
**Expenditure**
**Net gains /**
**(losses)**
**Transfers**
**At**
**31/12/2022**
**£**
**£**
**£**
**£**
**£**
**£**
-
285,069
(285,069)
-
-
-|
||-
285,069
(285,069)
-
-
-|
||66,589
-
(14,593)
-
-
51,996|
||66,589
-
(14,593)
-
-
51,996
14,681,404
5,127,405
(4,127,786)
(684,126)
-
14,996,897
1,608,529
-
-
(626,107)
-
982,422
724,533
-
-
-
-
724,533|
||17,081,055
5,127,405
(4,142,379)
(1,310,233)
-
16,755,848|
|||
||17,081,055
5,412,474
(4,427,448)
(1,310,233)
-
16,755,848|
Page 28
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **12 – Reconciliation of Movements in Funds (continued)**
|**Charity**
**Restricted Funds**
HEE Histopathology project
Total restricted funds
**Unrestricted Funds**
Designated Funds:
Jen Johnson Bursary
Total designated funds
Accumulated funds
Listed investment
revaluation reserve
Investment property
revaluation reserve
Total unrestricted funds
**Charity**
**Restricted Funds**
HEE Histopathology project
Total restricted funds
**Unrestricted Funds**
Designated Funds:
Jen Johnson Bursary
Total designated funds
Accumulated funds
Listed investment
revaluation reserve
Investment property
revaluation reserve
Total unrestricted funds|**At**
**01/01/2023**
**Income**
**Expenditure**
**Net gains /**
**(losses)**
**Transfers**
**At**
**31/12/2023**
**£**
**£**
**£**
**£**
**£**
**£**
-
384,214
(384,214)
-
-
-|
|---|---|
||-
384,214
(384,214)
-
-
-|
||51,996
-
(15,004)
-
-
36,992|
||51,996
-
(15,004)
-
-
36,992
14,167,007
4,208,813
(3,766,641)
(42,968)
673,057
15,239,268
982,422
-
-
808,815
-
(673,057)
1,118,180
724,533
-
-
(300,000)
-
424,533|
||15,925,958
4,208,813
(3,781,645)
465,847
-
16,818,973|
|||
||15,925,958
4,593,027
(4,165,859)
465,847
-
16,818,973|
||**At**
**01/01/2022**
**Income**
**Expenditure**
**Net gains /**
**(losses)**
**Transfers**
**At**
**31/12/2022**
**£**
**£**
**£**
**£**
**£**
**£**
-
285,069
(285,069)
-
-
-|
||-
285,069
(285,069)
-
-
-|
||66,589
-
(14,593)
-
-
51,996|
||66,589
-
(14,593)
-
-
51,996
14,427,722
3,609,416
(3,186,005)
(684,126)
-
14,167,007
1,608,529
-
-
(626,107)
-
982,422
724,533
-
-
-
-
724,533|
||16,827,373
3,609,416
(3,200,598)
(1,310,233)
-
15,925,958|
|||
||16,827,373
3,894,485
(3,485,667)
(1,310,233)
-
15,925,958|
Page 29
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **12 – Reconciliation of Movements in Funds (continued)**
The listed investment revaluation reserve represents the aggregate unrealised gains / (losses) on the fixed asset investment portfolio and current asset money market investments.
The investment property revaluation reserve represents the aggregate unrealised gains / (losses) on the investment property.
The Jen Johnson bursary gives successful applicants the opportunity to attend Congress (a biennial event) by providing help with the costs.
The Statement of Financial Activities of the Institute of Biomedical Science does not, in the opinion of the Council, reflect the group’s total activities without the consolidation of its subsidiary undertaking’s results. The Institute has, therefore, produced the group Statement of Financial Activities Account but, as permitted by the Companies Act 2006 and the Charities SORP, has not included the charitable company’s own Statement of Financial Activities Account.
## **13 – Analysis of Net Assets Between Funds**
||**2023**|**2023**|**2023**|
|---|---|---|---|
||**Unrestricted**|**Restricted**|**Total**|
||**£**|**£**|**£**|
|Tangible fixed assets|1,179,287|-|1,179,287|
|Fixed Asset Listed investments|11,425,990|-|11,425,990|
|Investment property|850,000|-|850,000|
|Current assets|5,642,570|573,633|6,216,203|
|Current liabilities|(1,295,999)|(573,633)|(1,869,632)|
||17,801,848|-|17,801,848|
||**2022**|**2022**|**2022**|
||**Unrestricted**|**Restricted**|**Total**|
||**£**|**£**|**£**|
|Tangible fixed assets|1,267,207|-|1,267,207|
|Fixed Asset Listed investments|10,600,327|-|10,600,327|
|Investment property|1,150,000|-|1,150,000|
|Current assets|4,908,681|720,765|5,629,446|
|Current liabilities|(1,170,367)|(720,765)|(1,891,132)|
||16,755,848|-|16,755,848|
## **14 - Pension Schemes**
The Institute operates a defined contribution scheme with Royal London to meet the requirements of the Auto Enrolment legislation. The Institute pays a contribution of 6% of salary during the employee’s probation period. On successful completion of the probation period the Institute pays twice the percentage that the employee contributes up to a maximum Institute contribution of 10% of salary.
The Institute operates a defined contribution scheme with AEGON. The Institute pays twice the percentage that the employee contributes up to a maximum Institute contribution of 10% of salary. The scheme is now closed to new entrants.
Total employer contributions into the defined contribution schemes in the year were £123,163 (2022: £105,005).
Page 30
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **14 - Pension Schemes (continued)**
There were employer and employee contributions totalling £nil (2022: £nil) outstanding at the year end.
## **15 – Auditors’ Remuneration**
The auditors’ remuneration (excl. VAT) for the period for the charity was £17,800 (2022: £16,250). In addition, the auditors provided audit and corporation tax services to Institute of Biomedical Science (Professional Services) Ltd which were subject to a separate agreement.
## **16 – Capital Commitments**
There were no capital commitments (2022: £nil) at the year end.
At the year end the Institute was negotiating a contract to replace the CRM system. A contract was signed in January 2024.
## **17 – Post Balance Sheet Events**
There were no post balance sheet events.
## **18 – Related Party Transactions**
The Institute owns 100% of the share capital in Institute of Biomedical Science (Professional Services) Ltd and its results are consolidated into these financial statements.
During the year 6 members of Council received payments totalling of £4,434 (2022: £5,030 for 7 Council members) for providing professional examination, accreditation and assessment services. In addition, payments totalling £1,389 (2022: £1,354) were paid to the spouse of a member of the senior management team for providing professional examination services. The payments were on the same basis as that made to others providing the same services.
The spouse of a member of the senior management team was deputy editor of the BJBS and received a payment of £600 (2022: £600). The payment was made on the same basis as that made to others providing the same services.
Two members of the senior management team were also trustees of the Science Council. During the year the Institute incurred costs of £97,020 (2022: £101,298) from the Science Council. The costs related to membership and registration services.
A member of the senior management team is also a director of the International Federation of Biomedical Laboratory Science (IFBLS). The cost of travel, accommodation and out of pocket expenses related to this role is met by IFBLS. The cost of the IFBLS subscription paid by the Institute for the year was £7,413 (2022: £7,631).
## **19 – Lessor Operating Lease Commitments**
The charity has entered into a non-cancellable operating lease as lessor for which the total of future minimum lease payments receivable (excluding VAT) as follows:
|Within one year
Later than one year but within five years
Total|**2023**
**£**
62,400
10,770
73,170|**2022**
**£**
10,600
-|
|---|---|---|
|||10,600|
Page 31
INSTITUTE OF BIOMEDICAL SCIENCE (377268)
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 (CONTINUED)**
## **20 – Comparative Statement of Financial Activity**
## **Consolidated Statement of Financial Activities for the Year Ended 31 December 2022**
## **(Incorporating the Income and Expenditure Account)**
|**Notes**
**Income from:**
Charitable activities
Subscriptions
Qualifications
Portfolios, assessments and accreditations
Publications
Regions, branches and discussion groups
2
Other income
Congress and other trading activities
7b
Investments
Listed investment income
Property rental
Bank interest
**Total Income**
**Expenditure on:**
Raising Funds
Congress and other trading activities
Investment management fees
Charitable activities
Education, qualifications and registration
3
Publications
3
Regions, branches and discussion groups
2,3
Member events, representation and benefits
3
Grants and prizes
**Total Expenditure**
Net (losses) / gains on investments
**Net (expenditure) / income**
**Other recognised gains / (losses)**
Gain on revaluation of investment property
**NET MOVEMENT IN FUNDS FOR THE YEAR**
Total funds brought forward
**Total funds carried forward**
13,14|**Unrestricted**
**Funds**
**Restricted**
**Funds**
**Total**
**2022**
**£**
**2022**
**£**
**2022**
**£**
2,390,123
-
2,390,123
344,706
285,069
629,775
373,983
-
373,983
6,671
-
6,671
121,031
-
121,031
2,110
-
2,110
1,600,093
-
1,600,093
196,220
-
196,220
63,107
-
63,107
29,361
-
29,361
5,127,405
285,069
5,412,474
1,120,784
-
1,120,784
79,489
-
79,489
1,371,445
285,069
1,656,514
109,312
-
109,312
191,134
-
191,134
1,232,172
-
1,232,172
38,043
-
38,043
4,142,379
285,069
4,427,448
(1,310,233)
-
(1,310,233)
(325,207)
-
(325,207)
-
-
-
(325,207)
-
(325,207)
17,081,055
-
17,081,055
16,755,848
-
16,755,848|**Total**
**2021**
**£**
2,440,341
390,696
327,929
34,674
6,633
572
27,949
177,097
64,237
1,130|
|---|---|---|
|||3,471,258|
|||143,078
82,726
1,320,800
99,977
66,872
1,421,822
30,296|
|||3,165,571|
|||913,223|
|||1,218,910
50,000|
|||1,268,910
15,812,145|
|||17,081,055|
Page 32